首頁 › 非小細胞肺癌 › 堪薩斯 › Kansas City
Kansas City, KS 的 非小細胞肺癌 臨床試驗
11 項針對 非小細胞肺癌 的研究正在 Kansas City(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
招募中1 期
- University of Kansas Medical Center, Kansas City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- University of Kansas Cancer Center, Kansas City
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The University of Kansas Cancer Center, Kansas City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- The University of Kansas Hospital, Kansas City
- The University of Kansas Medical Center Medical Office Building, Kansas City
- University of Kansas Hospital Cambridge North Tower A, Kansas City
- 還有 1 項
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- University of Kansas Cancer Center, Kansas City
- Veteran Administration Eastern Kansas Healthcare, Leavenworth · 距離 21 英里
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- University of Kansas Cancer Center, Kansas City
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
招募中1/2 期
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
招募中觀察性研究
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
招募中觀察性研究
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Kansas City 的其他研究
- 心血管疾病14 項研究
- 心臟衰竭13 項研究
- 肥胖症13 項研究
- 間質性肺病13 項研究
- 囊腫性纖維化13 項研究
- 乳癌12 項研究
- 膀胱癌12 項研究
- 急性髓系白血病12 項研究
- 前列腺癌12 項研究
- 肺癌11 項研究
- 慢性阻塞性肺病9 項研究
- 氣喘8 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。